Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: STU who wrote (875)	3/29/1998 7:52:00 PM
From: Russian Bear	Read Replies (1) \| Respond to of 1826

STU, <<Does Anyone have any ideas how HMAF aka MGI 114 is working on Humans?>> We do not know that yet, and will not know it for quite a while. That is what Phase II trials are all about. RB

To: STU who wrote (875)	3/29/1998 8:33:00 PM
From: David Cathcart	Respond to of 1826

Stu, <<I understand the dosage is Phase I is at the MTD of 14.15>> On Feb. 11th I posted this from the conference call that took place that day: "They are still at 14.15mg/m^2 dose level in phase I. They think is about the MTD for typical phase I patients that have advanced cancer and have already experienced extensive cancer treatments. They expect the MTD of patients that are not so weakened to be a little higher. They remain very optimistic about the value of MGI-114 and the moving into phase II. If the results from the lab are any guide, the effectiveness of this drug will be dramatically different when the tumors are not so large and extensive." Do you know anything more than this? Thanks. David